Arvinas, Inc. $ARVN shares purchased by Squarepoint Ops LLC. September 16, 2026 Key points. * Squarepoint Ops LLC increased its Arvinas stake by 760.3% in the second quarter, reaching 201,822 shares valued at approximately $1.68 million. Institutional investors and hedge funds collectively own 95.19% of ARVN. * Arvinas reported strong quarterly results, with $249.7 million in revenue - up 1,014.7% year over year - and earnings of $2.58 per share, exceeding analyst expectations. * ARVN shares opened at $8.26, while analysts maintained a consensus "Hold" rating and an average price target of $14.17; the company's CFO separately sold shares under a pre-arranged plan to cover tax obligations. * Interested in Arvinas? Here are five stocks we like better. Squarepoint Ops LLC boosted its position in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 760.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 201,822 shares of the company's stock after buying an additional 178,362 shares during the period. Squarepoint Ops LLC owned approximately 0.31% of Arvinas worth $1,677,000 as of its most recent filing with the Securities & Exchange Commission. Other institutional investors and hedge funds have also bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Arvinas in the second quarter worth $63,232,000. Armistice Capital LLC grew its position in Arvinas by 50.0% during the 4th quarter. Armistice Capital LLC now owns 1,800,000 shares of the company's stock worth $21,348,000 after purchasing an additional 600,000 shares during the period. Nantahala Capital Management LLC acquired a new stake in Arvinas during the 2nd quarter worth about $2,493,000. Man Group plc purchased a new position in shares of Arvinas during the 2nd quarter valued at about $2,128,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Arvinas during the 2nd quarter valued at about $2,119,000. 95.19% of the stock is currently owned by institutional investors and hedge funds. Insider transactions at Arvinas. In other Arvinas news, CFO Andrew Saik sold 5,696 shares of the business's stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $8.16, for a total transaction of $46,479.36. Following the completion of the sale, the chief financial officer directly owned 187,432 shares in the company, valued at approximately $1,529,445.12. The trade was a 2.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.30% of the stock is currently owned by insiders. Arvinas trading down 1.7%. Shares of ARVN opened at $8.26 on Wednesday. Arvinas, Inc. has a 12 month low of $6.97 and a 12 month high of $14.51. The stock's 50 day moving average is $8.73 and its two-hundred day moving average is $9.53. The firm has a market cap of $532.94 million, a P/E ratio of 82.61 and a beta of 1.75. Discover more Market Cap Calculator Space Stocks Report Arvinas (NASDAQ:ARVN - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of ($0.37) by $2.95. Arvinas had a return on equity of 1.91% and a net margin of 2.94%.The business had revenue of $249.70 million during the quarter, compared to the consensus estimate of $60.71 million. During the same period in the prior year, the company posted ($0.84) EPS. The business's quarterly revenue was up 1014.7% on a year-over-year basis. Equities research analysts forecast that Arvinas, Inc. will post 0.05 EPS for the current year. Wall Street analyst weigh in. ARVN has been the topic of a number of recent research reports. Zacks Research downgraded Arvinas from a "strong-buy" rating to a "hold" rating in a research note on Thursday, September 3rd. Evercore set a $14.00 price target on Arvinas in a research report on Monday, August 10th. Weiss Ratings raised Arvinas from a "sell (e+)" rating to a "sell (d)" rating in a report on Thursday, August 13th. BTIG Research restated a "buy" rating and issued a $18.00 price objective on shares of Arvinas in a research report on Tuesday, August 4th. Finally, Citigroup dropped their price objective on shares of Arvinas from $24.00 to $21.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $14.17. About Arvinas. Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively remove disease-causing proteins from cells. The company's approach, known as targeted protein degradation, uses proprietary PROTAC technology to direct specific proteins to the cell's natural disposal machinery. Arvinas applies this platform primarily to cancer and other serious diseases in which abnormal or unwanted proteins contribute to disease progression. Arvinas' pipeline has included vepdegestrant, formerly known as ARV-471, an investigational oral estrogen receptor degrader being developed for patients with estrogen receptor-positive, HER2-negative breast cancer. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Arvinas, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list. While Arvinas currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you'll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America. Continue following MarketBeat

Arvinas to participate in upcoming investor conferences. September 03, 2026 16:01 ET | Source: Arvinas Inc. NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) - Arvinas, Inc. (Nasdaq: ARVN) ("Arvinas" or the "Company"), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that that management will participate in fireside chats at the following upcoming investor conferences: * Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at 1:30 p.m. ET; webcast available here. * Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 2:10 p.m. ET; webcast available here. * Morgan Stanley Annual Global Healthcare Conference on Wednesday, September 16, 2026, at 9:15 a.m. ET; webcast available here. All webcasts will also be available in the Events and Presentations section of the Company's website. About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization. Arvinas is currently progressing multiple investigational drugs through or into clinical development programs, including ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy's disease; and ARV-6723, targeting HPK1 for advanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Arvinas reported progress on several strategic initiatives during its second quarter 2026 earnings call. The company achieved three key milestones this year: securing the first FDA approval for a PROTAC degrader, VEPPANU; completing an out-licensing deal for VEPPANU with Rigel Pharmaceuticals; and deciding to advance its KRAS G12D programme, ARV-806, only through a partnership. President and Chief Executive Officer Randy Teel said the company is focusing on advancing transformational improvements for patients through continued innovation and disciplined execution. The strategic decisions have positioned Arvinas to concentrate fully on its Phase I clinical programmes in oncology and neurology. The company determined that ARV-806 requires investment inconsistent with its current capital allocation strategy, though it believes the programme has potential as a meaningful treatment option.